Form 4: Artiva Biotherapeutics Director Granted Stock Options to Align Interests

Artiva Biotherapeutics Director Diego Miralles Gines was granted 13,750 stock options with an exercise price of $1.61, aligning his incentives with shareholder value.

Summary

• Diego Miralles Gines, a Director of Artiva Biotherapeutics, Inc. (ARTV), was granted 13,750 Director Stock Options on June 24, 2025.
• The options have an exercise price of $1.61 per share.
• The shares subject to the option will vest in full on the earlier of June 24, 2026, or the date of the Issuer's 2026 annual stockholder meeting.
• The options are exercisable until their expiration date of June 23, 2035.
• Following this transaction, Mr. Miralles Gines beneficially owns 13,750 derivative securities directly.

Sentiment

Score: 6

Explanation: The document reports a routine insider compensation event (grant of stock options) which is generally viewed as neutral to slightly positive as it aligns management interests with shareholders. There are no negative disclosures.

Positives

• The grant of stock options to Director Diego Miralles Gines aligns his interests with those of shareholders, as the options gain value only if the company's stock price increases above the exercise price of $1.61.
• The long expiration date of June 23, 2035, provides a significant window for the options to become in-the-money, indicating a long-term incentive for the director.

Future Outlook

The grant of stock options with a future vesting schedule indicates a long-term incentive for the director, aligning their future performance with the company's stock appreciation.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to attract, retain, and incentivize key personnel by aligning their financial interests with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The specific number of options (13,750) and the exercise price ($1.61) would typically be determined by the company's compensation committee based on factors such as the director's role, market compensation benchmarks for similar positions in the biotech industry, and the company's overall compensation philosophy.
• Without specific compensation committee reports or peer group data, a direct comparison to specific comparable companies or projects is not feasible from this Form 4.

Corporate Governance

Stakeholder Impact

• Shareholders: Potentially positive, as the director's interests are further aligned with increasing shareholder value through stock price appreciation.

Next Steps

• The granted stock options will vest in full on the earlier of June 24, 2026, or the date of Artiva Biotherapeutics' 2026 annual stockholder meeting.
• Following vesting, the director may choose to exercise the options at the specified exercise price of $1.61 per share before the expiration date of June 23, 2035.

Key Dates

Keywords

Artiva Biotherapeutics, ARTV, Form 4, stock options, insider transaction, director compensation, equity compensation, beneficial ownership